Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabAlexander M. Menzies, Georgina V. Long, Katy K. Tsai et al.|Annals of Oncology|2016Cited by 822
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysisJennifer L. McQuade, Michael A. Davies, Carrie R. Daniel et al.|The Lancet Oncology|2018Cited by 658
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancerJulie E. Lang, Laura J. Esserman, Andres Forero‐Torres et al.|npj Breast Cancer|2022Cited by 27
Patient satisfaction with telehealth as an element of hybrid decentralized clinical trials (DCTs): A cross-sectional study of oncology clinical trial participants.Andrew Parsonson, Annie Lau, Deme Karikios et al.|Journal of Clinical Oncology|2025Cited by 0